PLK1 and glioblastoma: The Angiopep-2 peptide was included as the targeting ligand, and consequently, the Cas9 RNP nanocapsule showed effective GBM tissue targeting (11.8% ID/g) and efficient Plk1 gene editing in the tumor (28.6% indel by Sanger sequencing) in a GBM mouse model.